Trastuzumab Deruxtecan scores two victories in HER2-positive early breast cancer

(MedPage Today) — BERLIN — Trastuzumab deruxtecan (T-DXd, Enhertu), an antibody-drug conjugate (ADC), showed impressive results in different settings of early-stage HER2-positive breast cancer in consecutive randomized clinical trials. In…